More than the first measurement

The heart signal hidden inside a night of sleep

An externally tested AI model finds predictive information in ECG recordings already collected during sleep studies.

A sleep study records more than breathing. It often contains a single-lead electrocardiogram—a stream of cardiac information collected while someone is asleep. A new modeling study asks whether that already-recorded signal can reveal more about future cardiovascular risk.

This is an appealing idea because it begins with data already obtained for another clinical purpose. But using an existing measurement more efficiently is not the same as proving that an extra risk score improves care.

How the model was tested

Researchers fine-tuned a deep neural network on overnight ECG and sleep-stage data from 15,809 Massachusetts General Hospital patients. They then evaluated it in separate cohorts at Emory, with 9,810 patients, and Beth Israel Deaconess, with 12,576.

The model’s output was associated with later atrial fibrillation, stroke, heart failure and mortality after adjustment for several conventional risk factors and sleep characteristics. For example, a one-standard-deviation increase in the output was associated with atrial-fibrillation hazard ratios of 2.03 and 2.72 in the two external cohorts.

Those ratios describe relationships between a score and later outcomes. They are not reductions in risk caused by using AI. Not every endpoint was equally consistent: the myocardial-infarction estimate in one validation cohort had a confidence interval crossing one.

Prediction is only part of the job

External validation is valuable, but clinical usefulness also requires reliable calibration, appropriate thresholds and a plan for the person receiving a high-risk result. A model can identify a statistical pattern without telling a clinician which action would improve that person’s health.

The study used outcomes derived from health records, including diagnostic codes. Differences in coding, referral patterns and the populations sent for sleep testing can affect generalizability. This is not evidence that every person needs a sleep study to screen for heart disease.

What would make the next study stronger

The next useful comparison would test what changes when clinicians receive the model’s result: appropriate evaluation, treatment decisions, patient experience, unnecessary testing and ultimately clinical outcomes. The burden of a false alarm belongs beside the possible benefit of earlier recognition.

The opportunity is not merely to collect more data. It is to discover whether information already present can answer a better question. That is a promising role for AI—as long as the pathway from prediction to useful care remains visible.

The same diet can ask different questions of different tissues

A mouse study separates dietary fat metabolism from ketones—and should not become a human cancer verdict.

A diet’s name is not a complete description of its biological effects. Ketogenic diets change fat exposure, carbohydrate availability, insulin signaling and ketone production together. A mechanistic study asks which of those changes mattered for intestinal tumors in cancer-prone mice.

That last phrase is essential. The experiment did not test whether a ketogenic diet causes cancer in people, and it did not estimate a personal cancer risk for someone choosing a way to eat.

Following the mechanism

In mouse models of spontaneous intestinal adenoma formation, the ketogenic diet increased tumor burden and shortened survival. The investigators manipulated the production and use of ketones, but those manipulations did not explain the tumor effects.

The stronger signal involved dietary lipids and their oxidation. Removing a set of intestinal PPAR regulators weakened the diet-associated expansion and activity of intestinal stem cells. Disrupting CPT1A, a component of fatty-acid oxidation, limited adenoma formation specifically under the ketogenic diet.

This is a useful example of why a mechanism should be tested rather than inferred from a label. “Ketogenic” does not establish that ketones caused every observed outcome.

The human boundary

Genetically susceptible mouse models are designed to make particular disease processes experimentally visible. Their responses may not represent those of humans with ordinary cancer risk. The abstract does not provide a human treatment comparison, a cancer-incidence estimate or a recommended dietary prescription.

The work is relevant to questions about inherited intestinal-cancer susceptibility, but clinical advice for such a person requires evidence and context beyond this experiment. It would be equally unjustified to use the findings to promote ketone supplements: the study does not establish their safety or benefit for cancer prevention.

A more useful nutrition conversation

The editorial lesson is not that one diet has now been declared good or bad. It is that tissue, genotype, food composition and measured outcome belong in the interpretation. A diet could change weight favorably while having other effects that need separate investigation.

For future research, the question is how much of the pathway carries into human biology and under what conditions. For a reader, the immediate gain is a sharper way to evaluate a headline: who was studied, what was changed, and what actually happened?

This was an August 2026 paper revisited in the October 13 edition. Its value lies in the precision of the experiment, not in presenting older mechanistic work as today’s clinical breakthrough.